期刊文献+

溴隐亭治疗女性高泌乳素血症并不育46例分析 被引量:6

The Application of Bromocriptine for Female Hyperprolactinemia and Infertility (A Report of 46 Cases)
下载PDF
导出
摘要 目的通过对溴隐亭治疗女性高泌乳素血症并不育的临床观察,探讨高泌乳素血症临床特点及溴隐亭治疗的方法。方法观察46例高泌乳素血症并不育患者的临床表现,实施溴隐亭治疗后动态B超监测排卵及子宫内膜情况。结果46例患者经溴隐亭治疗后,血清PRL均呈不同程度下降,排卵正常者41例,占89.1%,不孕35例中,半年内妊娠者23例,占65.7%;复发性流产者11例,9例继续妊娠大于5个月,占81.8%。结论高泌乳素血症患者因表现为排卵障碍、子宫内膜异常表现、黄体功能不足等导致不孕不育,溴隐亭治疗建议配合动态B超监测排卵指导用药,妊娠后视情况缓慢减少用量,并黄体支持。 Objective To discuss the characteristics of hyperprolactinemia and therapy of bromocriptine through the observation. Methods 46 cases hyperprolactinemia and infertility patients were observed and monitored by B-ultrasound on ovulation and endometrial situation. Results After 46 patients were treated by bromocriptine, serum PRL reduced to different degrees, normal ovulation 41 cases, accounting for 89.1% and 35 cases of infertility, within six months of pregnancy were 23 cases, accounting for 65.7%; Recurrent abortion were 11 cases, 9 cases continued to pregnant more than five months, accounting for 81.8%. Conclusion Hyperprolactinemia patients can cause infertility due to the performance of anovulation, endometrial abnormalities performance luteal insufficiency. We should choose medicine according to Bromocriptine and B-ultrasoud.
作者 周红
出处 《中国现代医生》 2007年第12Z期22-23,27,共3页 China Modern Doctor
关键词 高泌乳素血症 不育 溴隐亭 Hyperprolactinemia, Infertility Bromocriptine
  • 相关文献

参考文献3

二级参考文献24

  • 1Biller BM, Luciano A, Crosignani PG,et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med, 1999, 44[12 Suppl]:1075-1084.
  • 2Andrews ZB, Grattan DR. Opioid receptor subtypes involved in the regulation of prolactin secretion during pregnancy and lactation. J Neuroendocrinol, 2003, 15(3):227-236.
  • 3Phelps JY, Bugg EM, Shamblott MJ, et al. Prolaction gene expression in human ovarian follicular cells. Fertil Steril, 2003, 79(1):182-185.
  • 4Vera-Lastra O, Luis J, Luis R, et al. Prolactin and autoimmun. Autoimmun Rev, 2002, 1:360-364.
  • 5Serri O, Chik CL, Ur E, et al, Diagnosis and management of hyperprolactinemia. CMAJ, 2003, 169(6):575-581.
  • 6Emiliano AB, Fudge JL, From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology, 2004, 29(5):833-846.
  • 7Gurlek A, Nar A, Gedik O. Isolated adrenocorticotropic hormone deficiency, thyroid autoimmunity, and transient hyperprolactinemia. Endocr Pract, 2001, 7(2):102-105.
  • 8Inoue A, Seto M, Sugita S, et al, Differential effects on D2 doparnine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res Mol Brain Res, 1998, 55(2):285-289.
  • 9Valdemarsson S. Macroprolactinemia: Risk of misdiagnosis and mismanagement in hyperprolactinemia. Lakartidningen, 2004, 101 (6):458-465.
  • 10Vallette-Kasic S, Morange-Ramos I, Selim A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab, 2002,87:581-588.

共引文献40

同被引文献53

引证文献6

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部